← All trials
NCT05674669
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2015
- Primary completion
- Jul 26, 2016
- Completion date
- Jul 17, 2017
- First posted
- Jan 6, 2023
- Last posted
- Jan 6, 2023
- Enrollment
- 32
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eleusis TherapeuticsLead sponsor
- Eleusis TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.